Primary congenital glaucoma due to paternal uniparental isodisomy of chromosome 2 and CYP1B1 deletion

ConclusionsThis study is the first report of a homozygousCYP1B1 whole gene deletion due to paternal uniparental isodisomy of chromosome 2 as a cause of PCG. These results illustrate the importance of genetic testing in providing appropriate genetic counseling regarding the risks of recurrence.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: CLINICAL REPORT Source Type: research

Related Links:

CONCLUSIONS: The CDR and VCDR measurements provided by FD and SS OCT showed excellent agreement for the overall sample. When the devices were used for rim measurements, agreement was excellent only in the POAG patients. PMID: 31733916 [PubMed - as supplied by publisher]
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research
Children with nearsightedness (myopia) may now benefit from the first contact lens approved by FDA for slowing the progression of the common condition. Until now, traditional eyeglasses and contact lenses available in the United States have only been developed to correct blurred vision (a symptom of myopia), but not for slowing the progression of the condition.  “Today’s approval is the first FDA-approved product to slow the progression of myopia in children, which ultimately could mean a reduced risk of developing other eye problems,”...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
New J. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9NJ05393J, PaperMaja Zivkovic, Marko Zlatanovic, Nevena Zlatanovic, Mladjan Golubovi ć, Aleksandar M Veselinović Belonging to the group of cytokines, transforming growth factor- β, is involved in numerous physiological processes with two of its main receptors/kinases - transforming growth factor-β receptor type 1 and 2.... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
ACS NanoDOI: 10.1021/acsnano.9b07214
Source: ACS Nano - Category: Nanotechnology Authors: Source Type: research
Eye, Published online: 18 November 2019; doi:10.1038/s41433-019-0637-2Advanced glaucoma at diagnosis: current perspectives
Source: Eye - Category: Opthalmology Authors: Source Type: research
I read great interest the article by Hayashi and associates1 regarding the effect of 3 different topical antiglaucomatous agents on intraocular pressure (IOP) elevation after phacoemulsification in eyes with glaucoma. Similarly, in our recent prospective randomized study2 held on nonglaucomatous eyes, the authors suggested that brinzolamide is preferable for preventing an IOP spike after uneventful phacoemulsification. I have the following comments and concerns.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research
Publication date: Available online 15 November 2019Source: Chinese Chemical LettersAuthor(s): Ting Wang, Guanwen Qu, Yu Deng, Jing Shang, Zhangqi Feng, Fengyu Yang, Nongyue He, Jie ZhengAbstractThe prevalence of functionalized nanoparticles in biological and clinical fields attracts intensive toxicology investigations. Minimizing the nanoparticles’ biohazard remains a challenge due to the insufficient understanding on the nanoparticle-induced cell death mechanism. In the presented study, we observed the lysosome and genome injuries and so caused cell cycle changes and regulations of retinal ganglion neuron cell 5 (RG...
Source: Chinese Chemical Letters - Category: Chemistry Source Type: research
UAB has received a five-year, $3.5 million grant to study strategies to detect and manage glaucoma and other eye diseases in community-based settings. This grant will be focused on populations that are most at risk and the least likely to have access to eye care. The grant has been awarded to Lindsay Rhodes, assistant professor in the Department of Ophthalmology and Visual Sciences. The research plan seeks to implement and evaluate a telemedicine-based strategy in patients that are primarily treated…
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Condition:   Glaucoma Interventions:   Drug: Xalost S;   Drug: Xalatan;   Drug: Taflotan-S Sponsor:   Taejoon Pharmaceutical Co., Ltd. Recruiting
Source: - Category: Research Source Type: clinical trials
A University of Arizona Health Sciences study funded by a $2.3 million five-year grant from the National Institutes of Health National Eye Institute could help to develop future treatments for glaucoma and other diseases.
Source: The University of Arizona: Health - Category: Universities & Medical Training Authors: Source Type: research
More News: Australia Health | Genetics | Glaucoma | New Zealand Health | Study